When Dr. Goldfarb complains he gets results

We received his tweet

@NephJC #nephjc email I got about this was a shaker of salt but this JC is about WATER.

— David S Goldfarb (@weddellite) June 10, 2014

We replied with some snark

@weddellite yes, we are sorry. You know, saying things like that is why no one want to go to parties with nephrologists.

— Nephrology Journal C (@NephJC) June 10, 2014

But then we fixed the page on the website.

Old website implying that hyponatremia is a sodium problem...

...but any nephrologist worth his salt will tell you that hyponatremia is a water problem.

Michael Katz killing it with alternative hyponatremia flow charts

.@kidney_boy Actual Hospitalist Algorithm for Management of Hyponatremia. (presented in jest. sorta.) pic.twitter.com/nUwyVpboMz

— Michael Katz (@MGKatz036) June 8, 2014

.@moh7madhomod @kidney_boy Actually, I forgot this part of the Hospitalist Hyponatremia Algorithm: pic.twitter.com/KrWwVrOCjg

— Michael Katz (@MGKatz036) June 9, 2014

Goldfarb throws in his 2 cents on mild chronic hyponatremia

Goldfarb claims that arthropods can do science. I'll believe it when I see it.

#nephjc yes the ortho lit! Impact of mild chronic hypoNa: falls, fractures, osteoporosis,death Zaino CJ, Goldfarb DS Am J Orthop 2013;42:522

— David S Goldfarb (@weddellite) June 9, 2014

Pubmed reference here.

The Good, the Bad, and the Ugly. Over and over again.

'The good, the bad and the ugly' appears in the title of over 450 scientific papers. Just sayin' http://t.co/UvNkyXNLRN

— Dr John Weiner (@AllergyNet) June 9, 2014

and I bet every author thought they were being hip and original.

SYMPLICITY HTN-3 is now up on PubMed Commons

Comment of #NephJC 3 tweetchat and Google Hangout on Symplicity HTN 3 posted on @PubMedCommons http://t.co/C4ym3npATA

— Nephrology Journal C (@NephJC) June 5, 2014

Swapnil brought our SYMPLICITY coverage to PubMed, check it out.

And the winner is...

Last week we announced a contest to win a NephJC coffee mug

Sign up for our guaranteed only once-a-week #NephJC Newsletter and win a NephJC coffee mug. http://t.co/5aumn8rjuF pic.twitter.com/DbJUUAxu4K

— Nephrology Journal C (@NephJC) May 29, 2014

We had a surge of new people sign up for the newsletter and we have randomly selected a winner from this cohort. 

Marco Anaya Taboada of Bogota Columbia has won a NephJC mug. Now I just need to figure out how to ship one to South America.

Congratulations Marco!

Sign up for the NephJC Newsletter by going here.

SYMPLICITY HTN-3 Google Hangout

We were honored to have study author and Hypertension Demi-God, George Bakris join us to discuss the SYMPLICITY trial.

We were also joined by John Mandrola, Matt Sparks, Swapnil Hiremath and Joel Topf.

Enjoyed my first ever Google hangout > With the #NephJC team! @kidney_boy @Nephro_Sparks @hswapnil We discussed ablation in the kidneys.

— John Mandrola, MD (@drjohnm) June 4, 2014

#NephJC Hangout for SYMPLICITY HTN-3

We will take to the airwaves again to do our best Matt Lauer impressions tomorrow at 9 eastern. Be there or be somewhere else. (We need a better tag line)

Tuesday at 9pm NephJC #3: SYMPLICITY goes under the knife! - http://t.co/gOuYW0eemG

— Nephrology Journal C (@NephJC) June 2, 2014

Nephron On Demand continues to contribute to #NephJC

Tejas Desai put together an excellent abridged Storify of the Journal club. Check it out.

Great #nephrology #journalClub last night. Abridged/edited recap here https://t.co/wm5IRMnSUE #medstudents #FOAMed #meded #mdchat @hswapnil

— Nephrology On-Demand (@nephondemand) May 28, 2014

Nice coverage of #NephJC Symplicity discussion

Mass device did a nice little write up of our discussion last night

Must read story about Renal Denervation in Europe

"Of course we need to reflect on and take in the key learnings from SYMPLICITY HTN-3, but why should one trial all of a sudden erase all of the other data?"

-- EuroPCR course codirector, Dr William Wijns

Wijns disclosed receiving institutional grant support from Abbott Vascular, Biosensors International, Biotronik, Boston Scientific, Cordis, Medtronic, and St Jude Medical

---

“It is difficult to get a man to understand something, when his salary depends on his not understanding it.”

-- Upton Sinclair

---

Great article by Shelley Wood tipped by John Mandrola

Post #NephJC, I suggest @ShelleyWood2 piece - RDN Euro’s do not care, they r all bout burning kidneys. http://t.co/i1Rq3AyRl2 #shocking

— John Mandrola, MD (@drjohnm) May 28, 2014

Storify of #NephJC 3 • SYMPLICITY HTN-3

All the tweets that are fit to print

#NephJC 3: Symplicity • Analytics and Transcript

Symplicity brought down the house with 20 people participating in the chat generating 268 tweets and 326,103 impressions.

A Storify summary is forthcoming.

#JAMAPedsJC: The pediatricians show us how it is done

#JAMAPedsJC launched their first twitter journal club. Joyce Lee (@joyclee) organized this effort and did an outstanding job. The bar has been raised. You can see the introduction to the chat here.

The First NephJC Google Hangout

We are interested in finding innovative ways to share the collective wisdom of the nephrology community. The Twitter discussions have been excellent so far. Our next experiment is a Google Hangout, which is a video chat. The idea is that we will present a new journal article on alternating Tuesdays. Then on the off Tuesday we will broadcast a Google Hangout which will summarize the previous week's Twitter Chat and introduce the next week's journal club article. This will provide a tick-tock rhythm to NephJC.

We are new to Google Hangouts so we will be experimenting with various formats. For the first one we will have one of the article's authors, Vlado Perkovic join Joel Topf, Paul Phelan and Hiremath Swapnil on the Hangout. We will take audience questions during the hangout.

Each hangout will be recorded and added to commentary on the article.

Neph#JC Coffee mugs now available

It's a 15 oz (450 mL) mug because, let's face it, everyone knows that you have a coffee problem. No sense hiding it with a dainty cup. Go big. Zazzle swings NephJC a couple of bucks for every mug so we can start to pay off the hosting fees.

NephJC #2 - Atrasentan: Analytics and Transcript

A PDF of the transcript is available here.

NephJC coverage is linked to PubMed

Comment about #NephJC chat and author reactions posted on @pubmedcommons http://t.co/R3GBqvN5EP

— Nephrology Journal C (@NephJC) May 6, 2014

I fixed up the wikipedia article on atrasentan

The new journal club for Tuesday is a study of atrasentan for diabetic kidney disease. When I wrote introduction post I went to wikipedia and learned that atrasentan had been in trials as an antineoplastic agent. I went to the Twitter and asked if anyone was using it.

@MarkGaze is atrasartan still being investigated as a cancer treatment?

— Joel Topf (@kidney_boy) May 9, 2014

@kidney_boy Not to my personal knowledge. Also US National Cancer Institute clinical trials database doesn't come up with anything either.

— MD FRCP FRCR (@MarkGaze) May 9, 2014

He then gave me the keys to the kingdom by showing me where to search NCI site for trials. Bingo.

“@MarkGaze: @kidney_boy http://t.co/HCSwEbjGQB then enter the name of the drug as a keyword and press search.”

— Joel Topf (@kidney_boy) May 9, 2014

I was Quickly able to find the failed phase 3 trial and updated wikipedia.

@kidney_boy 994 patients required to demonstrate futility! We never get patient numbers like that in our paediatric trials.

— MD FRCP FRCR (@MarkGaze) May 9, 2014

Central American CKD

Why does the CKD screening matters? Because of this: http://t.co/HKuUTJgZvR @NephJC #nephJC

— Xavier F. Vela (@xaviervel) May 6, 2014